acid-phosphatase and Polycystic-Ovary-Syndrome

The goal of this study was to determine the effects of chronically elevated blood androstenedione and estrone levels on the quality and quantity of both cancellous (trabecular) and cortical bone in a young (mean age 9.4 years) female primate model (M. fascicularis). Thirteen intact female monkeys received continuous androstenedione/estrone supplementation via subcutaneous implants over a 24-month period to simulate the human condition known as polycystic ovarian disease (PCOD). A group of 16 untreated intact age-matched female monkeys served as controls. Lumbar spine and whole body bone mineral density (BMD) status was determined mid-study by dual photon absorptiometry (DPA); subsequent analysis of the bone related to data obtained following the 2-year treatment period without further BMD measurement. Bone markers, including serum acid phosphatase, total bone alkaline phosphatase, bone gla protein and tartrate-resistant acid phosphatase were measured at the end of the study. At necropsy, the lumbar vertebrae and femora were recovered in order to analyze the bone mineral quality and quantity of cancellous and cortical bone respectively and to compare these with the control group. Mineralization profiles of the vertebrae and femora were obtained using the density fractionation technique. Chemical analysis of the three largest fractions retrieved by density fractionation was performed to evaluate differences in %Ca, %P, Ca/P ratio and mineral content (%Ca + %PO4) between control and experimental groups. In addition, unfractionated bone powder was examined by X-ray diffraction to identify any changes in crystal size. Coronal sections of vertebrae were analyzed for structural parameters using histomorphometry and image analysis. Cross-sections taken at the midshaft diaphyseal femora were analyzed for structural macroscopic and intracortical parameters. There was a significant increase in BMD at the L2-L4 region in the treatment group compared with the control groups (p < 0.005) as measured at 1 year into the trial. Serum acid phosphatase was significantly lower (p < 0.05) in the treatment group compared with the controls near study termination. A nonsignificant shift in the mineralization profile of the vertebrae towards less dense bone was observed in the treatment group, while there was a significant shift in the mineralization profile towards more dense bone in the treated femora compared with controls (p < 0.05) after a 2-year period. There was no differen

Topics: Absorptiometry, Photon; Acid Phosphatase; Alkaline Phosphatase; Androstenedione; Animals; Biomarkers; Bone and Bones; Disease Models, Animal; Estrone; Female; Image Processing, Computer-Assisted; Macaca fascicularis; Osteocalcin; Photography; Polycystic Ovary Syndrome

Topics: Acid Phosphatase; Adolescent; Adult; Alkaline Phosphatase; Androgens; Biopsy; Collagen; Esterases; Female; Glycosaminoglycans; Gonadotropins, Pituitary; Humans; Hydroxysteroid Dehydrogenases; Hypothalamus; L-Lactate Dehydrogenase; Leiomyoma; Microscopy, Electron; Ovarian Neoplasms; Ovary; Polycystic Ovary Syndrome; Uterine Neoplasms